A recent study by Israel’s largest healthcare provider found that people after both doses of Pfizer vaccine were 94% less likely to have symptomatic COVID-19 infections and 92% fewer cases of serious illness due to the virus, Reuters reports.
Why it matters: Israel has rapidly vaccinated its population, and the new study highlights how effective the vaccine is, as the data are almost consistent with the clinical trial of Pfizer’s phase three, which showed that the vaccine is 95% effective.
Keep up to date with the latest market trends and economic insights with Axios Markets. Sign up for free
Where it says: According to Reuters, Clalit, the health system that covers most Israelis, compared 600,000 people who received both doses of Pfizer vaccine against an equally large group with similar medical histories who had not yet received the vaccine.
-
Researchers at the Weizmann Institute of Science have reported a decline in hospitalization and serious illness in people 55 and older.
-
“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it appears in the clinical study,” said Ran Balicer, Clalit’s head of innovation.
-
The data also indicate that the Pfizer vaccine is more effective “even two weeks or more after the second ingestion”.
Do you like this article? Get more from Axios and subscribe to Axios Markets for free.